Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06784466 · ClinicalTrials.gov registry record · NA
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
A NA study of Atrial Fibrillation (AF) and Paroxysmal AF, sponsored by Arga Medtech.
- Recruiting
- Registry status
- NA
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT06784466: Recruiting NA study of Atrial Fibrillation (AF) and Paroxysmal AF, sponsored by Arga Medtech.
NCT06784466 is a NA study of Atrial Fibrillation (AF) and Paroxysmal AF that is actively recruiting participants, run by Arga Medtech. The registered enrollment target is 360 participants, below the 698-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06784466, a NA study of Atrial Fibrillation (AF) and Paroxysmal AF, is actively recruiting participants, sponsored by Arga Medtech.
- RECRUITING
- Registry status
- NA
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and effectiveness of the Argá Medtech CSE Ablation System in the treatment of atrial fibrillation.
Primary Outcome
Primary safety events are: Within 7 days of the index procedure: * Complete heart block * Coronary spasm * Myocardial infarction * Peripheral or organ thromboembolism * Stroke * Transient ischemic attack * Unresolved phrenic nerve palsy * Vascular access complications * Pericarditis Within 30 days of the index procedure: * Acute renal failure * Cardiac tamponade / perforation * Cardiovascular or pulmonary Pulsed Field Ablation (PFA)-related hospitalization * Death * Gastroparesis * Major ble
Conditions Studied
Interventions
- DEVICE Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System
Study Locations (20)
Ohio
- TriHealth Cincinnati - Cincinnati
- Cleveland Clinic - Cleveland
- Ohio Health Research and Innovation Institute - Columbus
Other
- AZorg Aalst - Aalst
- Jessa Ziekenhuis - Hasselt
- KBC Split - Split
Georgia
- Emory - Atlanta
- Northside Hospital - Atlanta
Texas
- Texas Cardiac Arrhythmia Research Foundation - Austin
- Methodist - San Antonio
Alabama
- Grandview - Birmingham
Arizona
- Banner University Med Ctr - Phoenix
Arkansas
- Arrhythmia Research Group - Jonesboro
California
- UCSD - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2027-08 |
| Phase | NA |
What NCT06784466 shows while recruiting
NCT06784466 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, below the 698-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (48% lower).
The record links to 3 conditions, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 1 intervention - of which Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System is the first listed.
NCT06784466 names 20 study sites across 14 states, led by Ohio, Other, Georgia.
Frequently Asked Questions
What is clinical trial NCT06784466 about?
NCT06784466 is a clinical study titled "Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation". To evaluate the safety and effectiveness of the Argá Medtech CSE Ablation System in the treatment of atrial fibrillation.
What is the current status of trial NCT06784466?
This trial is currently recruiting. It is a NA study. The enrollment target is 360 participants. The study started on 2025-09-10. Estimated completion is 2027-08.
What conditions does trial NCT06784466 study?
This clinical trial studies the following conditions: Atrial Fibrillation (AF), Paroxysmal AF, Persistant Atrial Fibrillation.
What interventions are being tested in trial NCT06784466?
The interventions under investigation include: Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System (DEVICE).
Who is sponsoring clinical trial NCT06784466?
This trial is sponsored by Arga Medtech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06784466 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation (AF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06784466's enrollment target sits among peer trials
360 11th of 17 higher than 7 of 17 other Atrial Fibrillation (AF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation (AF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Digitally Rendered Interventions And Knowledge To Limit Ethanol-Associated Atrial Fibrillation Severity
RECRUITING · NA
-
Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
RECRUITING · NA
-
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
RECRUITING · NA
-
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
RECRUITING · NA
-
Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation
RECRUITING · NA
-
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI